RH Capital team launch new VC firm for women's health
The move reflects a maturation of the women’s health market.
The team behind the women’s health investment firm RH Capital have announced the launch of a new VC firm in a move reflecting a maturation of the women’s health market.
Foreground Capital will be led by Dr Alice Zheng, Stasia Obremskey and Elizabeth Bailey.
Explaining the rationale behind the launch, the trio said:
“With a positive market shift, we are ready to take the next step as an independent fund.
“This new structure will allow us to scale, attract additional capital, and keep investing in exceptional companies.”
Continued support for women’s health
Foreground Capital builds upon the foundation laid by RH Capital, which was originally incubated and launched by Rhia Ventures five years ago.
RH Capital has been a trailblazer in women’s health investing and was one of the first VC funds focused exclusively on women’s health. Over the past five years, RH Capital evolved into the largest dedicated portfolio of early stage venture investments in the sector with 20+ high-impact companies representing a diverse cohort of founders across life sciences, digital health, and tech-enabled services. At the close of RH Capital’s second fund, total assets under management reached $43.5 million.
The Foreground Capital team will continue to manage RH Capital Funds I/II and portfolio companies which include maternal health start-up Bloomlife, ovarian cancer diagnostics company AOA and at-home vaginal microbiome test Evvy.
Looking ahead, Foreground Capital plans to launch a new venture fund later this year, maintaining the focus on women’s health innovation and equity. This new chapter also presents an opportunity for the team to expand their work in women’s health.
Co-founder Elizabeth Bailey told FutureFemHealth:
"In our next fund, we're deepening our commitment to reproductive and maternal health, while also broadening our scope to include innovations that differentially and disproportionately impact women. This underscores the growing shift not only in our investment strategy, but also in the broader women's health landscape."